S 2689 REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness
US Congress 114th Congress
REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness
S.2689
About S.2689
REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness This bill amends the Public Health Service Act to require the Food and Drug Administration (FDA) to conditionally approve certain cellular therapeutic products without initiation of large-scale clinical trials. A conditionally approved cellular therapy may be marketed if certain conditions are met, including conditions on the source, processing, and function of the cells in the product.
Bill Texts
Introduced 03/17/2016
Weigh In
No votes yet!
Cast yours now to be the first.
Votes for: 0 Votes against: 0
Spread the Word!
Gettr
Sponsors (3)
